SCM
VRCA icon

Stonepine Capital Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Stonepine Capital Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-99,735
Closed -$528K – 103
2026
Q1 		$528K Sell
99,735
-253,934
-72% -$1.63M 0.21% 57
2025
Q4 		$2.94M Buy
+353,669
New +$1.96M 2.15% 12

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stonepine Capital Management's VRCA Position: Q2 2026 in Review

Stonepine Capital Management sold out of Verrica Pharmaceuticals (VRCA) in Q2 2026, closing a stake of 99,735 shares — an estimated $528K sold.

Stonepine Capital Management first reported a position in VRCA in Q4 2025 and held it in 2 quarters. The position peaked at $2.94M in Q4 2025. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

  • Stonepine Capital Management reported no remaining Verrica Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Stonepine Capital Management sold 99,735 Verrica Pharmaceuticals shares in Q2 2026, an estimated $528K.
  • Stonepine Capital Management first reported a position in Verrica Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Stonepine Capital Management's Verrica Pharmaceuticals position peaked at $2.94M in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.